Physiomics Regulatory News (PYC)

Physiomics Plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue

Oxford

OX4 4GA

UK

4th April 2018

Physiomics Plc

("Physiomics" or "the Company")

Physiomics to Present at the American Association for Cancer Research ("AACR") Annual Meeting

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the AACR Annual Meeting 2018, taking place at the McCormick Place Convention Center, Chicago, Illinois, on 14-18 April 2018. Dr Hitesh Mistry will present a poster based on the Company's recently completed personalised medicine project.

AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its annual conference is attended by the great and the good from public and private sector organisations from the very small to the largest global players, with over 21,000 participants attending from 80 countries in 2017.

Physiomics believes that the conference represents an excellent opportunity to showcase its capabilities, and will be sending a team of three, including CEO Dr Jim Millen. The Company will host a booth in the main meeting hall as well as present the results of its recently completed Innovate UK funded research project on the personalised treatment of oesophageal cancer. The Company plans to use the opportunity of the conference to touch base with current clients, all of whom will be represented there, as well as to hold targeted meetings with potential future clients.

The abstract ("A decision support system for the treatment of oesophageal cancer", Abstract No. LB-025) will be presented in the "Late-Breaking Research: Bioinformatics and Systems Biology" poster session, scheduled April 15th, 2018 1:00 PM - 5:00 PM.

More information about the conference may be found at:

http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=136&DetailItemID=642 

For further information please contact:

Physiomics Plc

Dr Jim Millen

+44 (0)1865 784980

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.